cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cabaletta Bio Inc
7 own
12 watching
Current Price
$0
$0.26
(2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
386.75M
52-Week High
52-Week High
13.44
52-Week Low
52-Week Low
0.59
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization386.75M
icon52-Week High13.44
icon52-Week Low0.59
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Cabaletta Bio Inc do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More
How much money does Cabaletta Bio Inc make?
News & Events about Cabaletta Bio Inc.
Globe Newswire
2 months ago
IND application cleared within 6 months of in-licensing CABA-201 binder CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the patient dosing intervals PHILADELPHIA, March 31, 2023 (...
Ticker Report
2 months ago
Cabaletta Bio (NASDAQ:CABA Get Rating)s stock had its buy rating restated by equities research analysts at Chardan Capital in a research note issued on Wednesday, Benzinga reports. They currently have a $12.00 price objective on the stock. Chardan Capitals target ...
Globe Newswire
2 months ago
Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (...
Globe Newswire
5 months ago
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The ...
Globe Newswire
5 months ago
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Cabaletta Bio Inc share price today?
plus_minus_icon
Can Indians buy Cabaletta Bio Inc shares?
plus_minus_icon
How can I buy Cabaletta Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Cabaletta Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cabaletta Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Cabaletta Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Cabaletta Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cabaletta Bio Inc?
plus_minus_icon
What percentage is Cabaletta Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cabaletta Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.26
(2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00